Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
BOLT Stock Chart & Stats
$4.55
-$0.02(-3.16%)
At close: 4:00 PM EST
$4.55
-$0.02(-3.16%)
Day’s Range― - ―
52-Week Range$4.42 - $13.40
Previous CloseN/A
Volume72.19K
Average Volume (3M)29.18K
Market Cap
$9.67M
Enterprise Value-$305.28K
Total Cash (Recent Filing)$34.77M
Total Debt (Recent Filing)$24.18M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Apr 01, 2026EPS EstimateN/A
Last Dividend Ex-Date
Aug 29, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,919,441
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)7.14
Price to Sales (P/S)53.13
P/FCF Ratio-6.66
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$29.33Price Target Upside544.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyIn Ph 1 dose escalation, the asset showed an encouraging signal as a single agent in three non-small cell lung cancer patients, including one confirmed partial response in a heavily pre-treated patient.
Financial StabilityBolt finished the quarter with $48.5M in cash, cash equivalents, and investments, which they expect to fund operations through mid-2026.
Innovative TreatmentBolt Biotherapeutics' lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates since the payload is an immune-stimulatory agent instead of a cytotoxic warhead.
Bears Say
Clinical Trial RisksThe trial is enrolling patients with CLDN18.2-expressing tumors, which may present challenges in achieving consistent results.
Market SentimentBolt's enterprise value is negative, indicating low Street expectations for BDC-4182.
Operational ChallengesBolt is reducing its workforce by approximately 50%, which shall extend its cash runway into 2027.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $4.42 and its highest was $13.40 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $9.67M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 141 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Currently, no data Available
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,919,441 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics (BOLT) is a biotechnology company focused on developing innovative immuno-oncology therapies that harness the power of the immune system to target and destroy cancer cells. The company specializes in creating proprietary platforms that combine its expertise in antibody engineering with cutting-edge technologies to develop treatments for various types of cancer. Bolt's core products and services include its proprietary Boltbody™ platform, which is designed to enhance the efficacy of cancer therapies by improving the targeting and activation of immune cells.
BOLT Stock 12 Month Forecast
Average Price Target
$29.33
▲(544.62% Upside)
Technical Analysis
Ownership Overview
3.08% Insiders
5.83% Mutual Funds
<0.01% Other Institutional Investors
89.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---